U.S. market Closed. Opens in 2 days 6 hours 12 minutes

ELYM | Eliem Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/AN/AN/AN/AN/A
Cost of RevenueN/AN/AN/AN/AN/A
Gross ProfitN/AN/AN/AN/AN/A
Operating Expenses37.41M45.13M35.67M11.77M4.70M
Selling, General & Admin9.89M18.92M12.35M2.42M677.00K
Research & Development15.41M26.21M23.32M9.34M4.02M
Other Operating ExpensesN/A1.38M-11.64MN/A914.00K
Operating Income-21.47M-45.13M-35.67M-20.93M-7.45M
Other Expenses / Income-13.65M-109.00K-11.81M257.00K899.00K
Before Tax Income-35.12M-45.24M-47.48M-20.67M-6.55M
Income Tax Expenses-21.47K109.00K-66.56K-9.16M-2.75M
Net Income-35.12M-45.35M-47.48M-11.51M-3.80M
Interest ExpensesN/A1.59MN/AN/AN/A
Basic Shares Outstanding26.99M26.31M26.24M26.32M26.32M
Diluted Shares Outstanding26.99M26.31M26.24M26.32M26.32M
EBITDA-13.65M-43.65M-35.50M-2.87M-1.93M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
EBIT-35.14M-43.65M-47.55M-20.67M-6.55M
EBIT Margin0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙